Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 39: 2419-2430, 1993;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Galpin, A. J.
Right arrow Articles by Evans, W. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Galpin, A. J.
Right arrow Articles by Evans, W. E.

Clinical Chemistry, Vol 39, 2419-2430, Copyright © 1993 by American Association for Clinical Chemistry

Therapeutic drug monitoring in cancer management

AJ Galpin and WE Evans
Pharmaceutical Department, St. Jude Children's Research Hospital, Memphis, TN 38101-0318.

Several anticancer drugs display characteristics that make them suitable candidates for therapeutic drug monitoring (TDM), including substantial pharmacokinetic variability and a narrow therapeutic index. However, concentration-effect relationships (pharmacodynamics) of most antineoplastic agents have not been well defined, thus limiting the widespread clinical application of TDM for cancer chemotherapy. Strategic incorporation of pharmacokinetic studies during phase I-III clinical trials should facilitate the identification of concentration- effect relationships and the definition of clinically useful levels of treatment intensity. We review representative clinical studies that have defined pharmacodynamic relationships for methotrexate, teniposide, etoposide, carboplatin, and mercaptopurine. Given that TDM has impacted positively on the clinical use of many drugs belonging to other therapeutic classes, and that pharmacodynamic correlations have been identified in several recent studies of anticancer drugs, we consider implementation of TDM a rational strategy for optimizing the use of selected antineoplastics.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Cancer Res.Home page
K. Hande, M. Messenger, J. Wagner, M. Krozely, and S. Kaul
Inter- and Intrapatient Variability in Etoposide Kinetics with Oral and Intravenous Drug Administration
Clin. Cancer Res., October 1, 1999; 5(10): 2742 - 2747.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. A. Coulthard, C. Howell, J. Robson, and A. G. Hall
The Relationship Between Thiopurine Methyltransferase Activity and Genotype in Blasts From Patients With Acute Leukemia
Blood, October 15, 1998; 92(8): 2856 - 2862.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
Y. Y. Hon and W. E. Evans
Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach
Clin. Chem., February 1, 1998; 44(2): 388 - 400.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
P. D. Walson
Therapeutic drug monitoring in special populations
Clin. Chem., February 1, 1998; 44(2): 415 - 419.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by the American Association for Clinical Chemistry.